{
    "nctId": "NCT00253422",
    "briefTitle": "Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer",
    "officialTitle": "A Partially-Blind Phase III Randomized Trial of Fulvestrant (Faslodex\u2122) With or Without Concomitant Anastrozole (Arimidex\u2122) Compared With Exemestane in Postmenopausal Women With ER+ve Locally Advanced/Metastatic Breast Cancer Following Progression on Non-Steroidal Aromatase Inhibitors",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 750,
    "primaryOutcomeMeasure": "Progression-free survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed adenocarcinoma of the breast\n\n  * Locally advanced or metastatic disease\n* Metastatic disease must be measurable or evaluable\n\n  * Patients with bone only metastases are eligible provided there is an evaluable site of bone metastasis that can be followed by x-ray, MRI, or CT scan\n* Relapsed or progressed during prior treatment with single-agent nonsteroidal aromatase inhibitor (NSAI)\\*, meeting either of the following criteria:\n\n  * NSAI given as adjuvant therapy that lasted \u2265 12 months\n  * Achieved an objective complete response, partial response, or stable disease that lasted \u2265 6 months after prior first-line therapy with NSAI for locally advanced or metastatic disease\n\n    * Chemotherapy as part of the first-line therapy given before initiation of NSAI allowed NOTE: \\*Patients are required to continue to take NSAI until beginning of study treatment.\n* No rapidly progressive visceral disease (i.e., lymphangitis carcinomatosa or diffuse hepatic involvement)\n* Hormone receptor status:\n\n  * Estrogen receptor (ER) and/or progesterone receptor positive tumor\n  * No ER-unknown disease\n\nPATIENT CHARACTERISTICS:\n\nSex\n\n* Female\n\nMenopausal status\n\n* Postmenopausal, as defined by 1 of the following criteria:\n\n  * Age 60 and over\n  * Age 45 to 59 AND \u2265 12 months since last menstrual period with no prior hysterectomy\n  * Any age with prior bilateral oophorectomy\n\nPerformance status\n\n* WHO 0-2\n\nLife expectancy\n\n* More than 3 months\n\nHematopoietic\n\n* Neutrophil count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n\n  * No thrombocytopenia\n* Hemoglobin \u2265 10 g/dL\n\nHepatic\n\n* AST and ALT \u2264 2.5 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 5 times ULN (unless due to bone metastases)\n* No liver disease\n\nRenal\n\n* Creatinine \\< 1.97 mg/dL\n\nOther\n\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n\nPRIOR CONCURRENT THERAPY:\n\nChemotherapy\n\n* See Disease Characteristics\n* Prior neoadjuvant or adjuvant chemotherapy allowed\n\nEndocrine therapy\n\n* See Disease Characteristics\n* Prior tamoxifen as neoadjuvant or adjuvant therapy allowed\n* No systemic corticosteroids that lasted \\> 15 days within the past 4 weeks\n\nOther\n\n* More than 4 weeks since prior investigational drugs\n* Concurrent bisphosphonates for bone metastases allowed provided bisphosphonate therapy has been established for \u2265 6 months\n\n  * Concurrent initiation of bisphosphonate allowed provided patient has soft tissue or visceral metastases as the measurable or evaluable target lesion\n* No concurrent anticoagulant therapy\n* No concurrent unlicensed noncancer investigational agents",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}